Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol PK and Safety in Hospitalized Infants From Birth to <3 Months With Suspected or Confirmed Gram-negative Infections
2023-503757-35-00Phase 2Withdrawn
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of cefiderocol in Gram-negative bacterial infection, complicated urinary tract infection (cUTI), Intra-abdominal infection (IAI) and 4 more, sponsored by Shionogi & Co., Ltd. Planned start Oct 2023; status: withdrawn.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infectioncomplicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2023-503757-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503757-35-00.